CVS Jumping on Cost-plus Bandwagon
Pharmacy benefit managers have been under pressure to simplify their complicated, obscure pricing tactics.
CVS Health is joining pharmacy benefit managers by offering simpler, cost-plus pricing, although it won't be available until 2025.
“CVS CostVantage will define the drug cost and related reimbursement with contracted pharmacy benefit managers (PBMs) and payers, using a transparent formula built on the cost of the drug, a set markup, and a fee that reflects the care and value of pharmacy services,” the company said in a news release this morning in advance of its investor’s day event.
CVS Pharmacy plans to launch CVS CostVantage with PBMs for their commercial payers in 2025, according to the news release.
The news release also announced the launch of a program called TrueCost, which the company will offer “client pricing reflecting the true net cost of prescription drugs, with visibility into administrative fees.” It will also be available in 2025.
Cigna Group’s Express Scripts announced plans to offer a “cost-plus” drug pricing model in November.
Pharmacy benefit managers (PBMs) especially the ‘big three” — CVS Caremark, Express Scripts and Optum Rx — have been under pressure to make their complicated, often obscure pricing tactics more transparent. Mark Cuban, the owner of the NBA’s Dallas Mavericks and a “Shark Tank” judge, co-founded Mark Cuban Cost Plus Drugs in early 2022 with a simple mark-up pricing strategy that Express Scripts and CVS Caremark appear to be emulating.
Several PBM reform bills have been introduced in Congress that would also require more reporting and transparency.
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades
June 13th 2025The FDA has accepted a New Drug Application for zoliflodacin, a first-in-class oral antibiotic for treating uncomplicated gonorrhea, offering a potential new option amid rising antibiotic resistance.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
